David H. Henry, MD, on Advances in Lung Cancer, Colorectal Cancer: Expert Perspective
2017 ASCO Annual MeetingDavid H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.
Related Videos
Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)
Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in mal...
Lee S. Schwartzberg, MD: 2017 Update on ICLIO: Adopting Immunotherapy in the Community Setting
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results
David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and ...
Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institu...
Bernard J. Escudier, MD, and Sumanta K. Pal, MD, on RCC: Trial Results on Sunitinib
Bernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to t...
